Key Highlights

  • Net loss per share was USD 0.42, against an estimate of a USD 0.44 loss.
  • Net loss narrowed to USD 17.90 million from USD 18.23 million.
  • Research and development expenses rose to USD 14.55 million from USD 13.65 million.
  • Cash, equivalents and investments totaled USD 77.8 million at September 30, 2026.

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology Business whose precision medicines rest on an in-house system called the Acrivon Predictive Precision Proteomics platform, or AP3. It recorded no Revenue in the third quarter of 2026 or in the same period a year earlier, so its results turn on spending and cash.

The net loss for the quarter was USD 17.90 million, compared with USD 18.23 million a year before. Basic and diluted net loss per share was USD 0.42, compared with USD 0.47, and the estimate had been a loss of USD 0.44.

Where the Spending Went

Research and development expenses rose to USD 14.55 million from USD 13.65 million, while general and administrative expenses fell to USD 3.97 million from USD 6.04 million. Total operating expenses were USD 18.52 million, compared with USD 19.69 million, and the loss from operations matched those totals in both periods.

Interest income was USD 748 thousand, compared with USD 1.51 million, and other expense, net, was USD 127 thousand, compared with USD 53 thousand. Total other income, net, was USD 621 thousand, down from USD 1.45 million. Weighted average common stock outstanding was 42,876,572, compared with 38,560,464.

Nine Months in Review

Over the nine months ended September 30, 2026, Research and Development expenses were USD 43.56 million, compared with USD 45.24 million, and general and administrative expenses were USD 13.53 million, compared with USD 18.75 million. The loss from operations was USD 57.09 million, compared with USD 64.00 million.

The nine-month net loss was USD 54.90 million, against USD 58.92 million, which equals USD 1.33 per share, compared with USD 1.53. The comprehensive loss was USD 55.04 million, compared with USD 59.26 million.

Cash, Runway and Funding Needs

Cash and cash equivalents were USD 47.54 million at September 30, 2026, compared with USD 41.50 million at December 31, 2025, while short-term investments were USD 30.22 million, compared with USD 77.08 million. Together, cash, cash equivalents and investments totaled USD 77.8 million. The company believes that sum covers operating expenses and Capital spending needs through to the fourth quarter of 2027.

Total Assets were USD 85.75 million, compared with USD 129.72 million. Total current liabilities were USD 14.28 million, compared with USD 15.66 million, and total liabilities were USD 14.97 million, compared with USD 17.20 million.

The Liquidity section of the filing also records the company's review of Going Concern status under the relevant accounting standards. It points to a requirement for further funding of operations and to the possibility that research and development programs may have to be delayed, reduced or terminated.